Inhibikase Therapeutics Inc IKT:NASDAQ

RT Quote | NASDAQ | USD
Last | 02/26/21 EST
6.70quote price arrow down-0.39 (-5.50%)
Volume
64,324
52 week range
6.40 - 11.80

...

Loading . . .

KEY STATS

  • Open7.18
  • Day High7.44
  • Day Low6.65
  • Prev Close6.70
  • 52 Week High11.80
  • 52 Week High Date12/23/20
  • 52 Week Low6.40
  • 52 Week Low Date01/27/21
  • Market Cap67.60M
  • Shares Out10.09M
  • 10 Day Average Volume0.12M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.48
  • P/E (TTM)-13.83
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-4.505M
  • ROE (MRQ)-
  • Revenue (MRQ)800,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-565.04%
  • Debt To Equity (MRQ)-13.96%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Inhibikase Therapeutics Inc News

There is no recent news for this security.

Latest IKT News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Inhibikase Therapeutics Inc. is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s lead product candidate, IkT-148009 is for the treatment of PD, and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009, is a brain penetrant c-Abl protein kinase inhibitor that halts disease...
Address
3350 Riverwood Parkway Se, Suite 1900
Atlanta, GA
30339
United States